Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 812 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Announces 2026 Fellowship Recipients Supporting Innovation in Cancer Research, Artificial... September 1, 2026 Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... March 11, 2021 ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... July 31, 2020 Air Pollution and Breast Cancer Risk – A Link That Calls... October 17, 2023 Load more HOT NEWS FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC Trialling a new way to boost CAR T-cell therapy
